volociximab + liposomal doxorubicin

Volociximab + liposomal doxorubicin is a combination therapy under investigation primarily for advanced epithelial ovarian cancer and primary peritoneal cancer[1][3]. **Volociximab** is a chimeric monoclonal antibody targeting α5β1 integrin, inhibiting angiogenesis (formation of new blood vessels) crucial for tumor growth and metastasis. **Liposomal doxorubicin** (pegylated liposomal doxorubicin, commonly marketed as Doxil or Lipodox) is a formulation of the anthracycline chemotherapy drug doxorubicin encapsulated in liposomes, which helps prolong drug retention in the bloodstream and improve tumor targeting while reducing toxicity[2][4][5]. Liposomal doxorubicin works primarily by inhibiting topoisomerase II, causing DNA damage and cell death in rapidly dividing cancer cells. The combination is intended to leverage volociximab’s anti-angiogenic effect with the cytotoxic activity of doxorubicin for enhanced antitumor efficacy in platinum-resistant ovarian cancer and related malignancies[1][3][5]. This combination is administered intravenously in clinical trial settings.

Brand names

Lipodox

Other names

volociximabliposomal doxorubicindoxorubicin hydrochloride liposome